CA2408710C - Compositions et methodes de traitement du cancer colorectal - Google Patents

Compositions et methodes de traitement du cancer colorectal Download PDF

Info

Publication number
CA2408710C
CA2408710C CA2408710A CA2408710A CA2408710C CA 2408710 C CA2408710 C CA 2408710C CA 2408710 A CA2408710 A CA 2408710A CA 2408710 A CA2408710 A CA 2408710A CA 2408710 C CA2408710 C CA 2408710C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
irinotecan
solvate
hydrate
thalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2408710A
Other languages
English (en)
Other versions
CA2408710A1 (fr
Inventor
Rangaswamy Govindarajan
Andrew Zeitlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
University of Arkansas at Little Rock
Original Assignee
Celgene Corp
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, University of Arkansas at Little Rock filed Critical Celgene Corp
Publication of CA2408710A1 publication Critical patent/CA2408710A1/fr
Application granted granted Critical
Publication of CA2408710C publication Critical patent/CA2408710C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne des compositions renfermant de la thalidomide et de l'irinotecan qui peuvent être utilisées pour le traitement ou la prévention du cancer colorectal. L'invention concerne également des méthodes de traitement ou de prévention du cancer colorectal qui consistent à administrer de la thalidomide ou de l'irinotecane à un patient qui en a besoin. De plus, cette invention concerne des méthodes permettant de réduire ou d'éviter les effets secondaires dommageables liés à l'irinotecan, qui consistent à administrer de la thalidomide à un patient chez lequel de tels effets doivent être atténués ou évités.
CA2408710A 2000-05-15 2001-05-10 Compositions et methodes de traitement du cancer colorectal Expired - Fee Related CA2408710C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20414200P 2000-05-15 2000-05-15
US60/204,142 2000-05-15
PCT/US2001/015326 WO2001087306A2 (fr) 2000-05-15 2001-05-10 Compositions et methodes de traitement du cancer colorectal

Publications (2)

Publication Number Publication Date
CA2408710A1 CA2408710A1 (fr) 2001-11-22
CA2408710C true CA2408710C (fr) 2010-01-26

Family

ID=22756801

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2408710A Expired - Fee Related CA2408710C (fr) 2000-05-15 2001-05-10 Compositions et methodes de traitement du cancer colorectal

Country Status (12)

Country Link
US (2) US6914067B2 (fr)
EP (1) EP1286671B1 (fr)
JP (1) JP4679028B2 (fr)
AT (1) ATE322265T1 (fr)
AU (2) AU2001261473B2 (fr)
CA (1) CA2408710C (fr)
DE (1) DE60118547T2 (fr)
DK (1) DK1286671T3 (fr)
ES (1) ES2261415T3 (fr)
NZ (1) NZ522766A (fr)
PT (1) PT1286671E (fr)
WO (1) WO2001087306A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
CA2454627A1 (fr) * 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Moyens et procedes ameliorant le traitement du cancer sur la base de mrp1
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (fr) 2002-10-15 2008-03-19 Celgene Corporation Procédé d'utilisation et compositions comprenant des composés immunomodulateurs pour le traitement et la gestion de syndromes myélodysplasiques
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) * 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US6987012B2 (en) * 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
EP1684758A4 (fr) * 2003-11-06 2009-02-18 Celgene Corp Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
CA2821167C (fr) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Liposomes pour l'administration de drogues contenant des polyols anioniques ou des sucres anioniques
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CA2503099A1 (fr) * 2005-04-18 2006-10-18 Kabushiki Kaisha Yakult Honsha Compositions pharmaceutiques renfermant des camptothecines
EP1881835A4 (fr) * 2005-05-19 2010-04-07 Prometic Biosciences Inc Composes de triazine et leurs compositions utilises dans le traitement des cancers
JP2009509171A (ja) * 2005-09-21 2009-03-05 シーシーシー ダイアグノスティックス， エルエルシー 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
US20070219825A1 (en) * 2005-11-23 2007-09-20 Maetzold Derek J Method of managing and reducing side effects associated with exposure to a drug
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
PL3337478T5 (pl) 2015-08-21 2026-05-04 Ipsen Biopharm Ltd. Kombinacja leków obejmująca liposomalny irynotekan, oksaliplatynę, 5-fluorouracyl i leukoworynę do leczenia nowotworu trzustki z przerzutami
AU2016340153B2 (en) 2015-10-16 2022-06-02 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
ES2968415T3 (es) 2016-02-09 2024-05-09 Sun Pharmaceutical Ind Ltd Sistema de perfusión
EP3535026A1 (fr) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20230084382A1 (en) * 2019-08-19 2023-03-16 Merus N.V. Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
AU746875B2 (en) * 1997-02-27 2002-05-02 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea

Also Published As

Publication number Publication date
ES2261415T3 (es) 2006-11-16
WO2001087306A8 (fr) 2002-10-03
AU6147301A (en) 2001-11-26
DE60118547T2 (de) 2007-02-01
EP1286671A2 (fr) 2003-03-05
ATE322265T1 (de) 2006-04-15
AU2001261473B2 (en) 2006-09-14
US20050203060A1 (en) 2005-09-15
US7479499B2 (en) 2009-01-20
US6914067B2 (en) 2005-07-05
CA2408710A1 (fr) 2001-11-22
HK1053975A1 (en) 2003-11-14
NZ522766A (en) 2005-09-30
EP1286671B1 (fr) 2006-04-05
DE60118547D1 (de) 2006-05-18
WO2001087306A2 (fr) 2001-11-22
JP4679028B2 (ja) 2011-04-27
JP2003533483A (ja) 2003-11-11
DK1286671T3 (da) 2006-07-17
PT1286671E (pt) 2006-08-31
US20020035091A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001261473B2 (en) Compositions and methods for the treatment of colorectal cancer
AU2001261473A1 (en) Compositions and methods for the treatment of colorectal cancer
DE60118571T2 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
CN100579527C (zh) 用于治疗和控制脊髓发育不良综合征的含免疫调节化合物的组合物和使用方法
PT1505973E (pt) Combinações para o tratamento de mieloma múltiplo
US20010012850A1 (en) Methods and compositions for inhibition of angiogenesis
AU2001261474A1 (en) Compositions and methods for the treatment of cancer
US6274601B1 (en) Methods of inhibiting ulcerative mucositis
US6890906B2 (en) Method for controlling angiogenesis in animals
CA2563748A1 (fr) Procede d'utilisation de la thalidomide et compositions la renfermant pour le traitement et la gestion de l'hypertension pulmonaire
CA2543312A1 (fr) Procedes et compositions a base de thalidomide pour le traitement des fibromyalgies
EP2097085A2 (fr) Matériaux et procédés thérapeutiques
HK1053975B (en) Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
IL319025A (en) Methods for treating or preventing endometriosis
EP1676577A1 (fr) Compositions pour le traitement du cancer contenant un inhibiteur de topoisomerase et thalidomide
KR20100058662A (ko) 개에게서 림프종을 치료하기 위한 이다루비신
JPH02178227A (ja) 腎炎治療剤
AU5039401A (en) Medicaments
Vet—QC02CA04 Doxazosin Mesilate (BANM, rINNM)
HK1054502B (en) Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
HK1093677A (en) Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160510